Biotech Consortium India Limited (BCIL) Revenue and Competitors

New Delhi, India

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biotech Consortium India Limited (BCIL)'s estimated annual revenue is currently $6M per year.(i)
  • Biotech Consortium India Limited (BCIL)'s estimated revenue per employee is $77,500

Employee Data

  • Biotech Consortium India Limited (BCIL) has 78 Employees.(i)
  • Biotech Consortium India Limited (BCIL) grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.5M1610%N/AN/A
#2
$17.3M22318%N/AN/A
#3
$11.1M14334%N/AN/A
#4
$6.9M896%N/AN/A
#5
$8.7M11224%N/AN/A
#6
$19.6M25316%N/AN/A
#7
$12M1558%N/AN/A
#8
$17.1M22054%N/AN/A
#9
$11.5M148-5%N/AN/A
#10
$6.9M8924%N/AN/A
Add Company

BCIL was incorporated as public limited company in 1990 under the Indian Companies Act 1956. It is promoted by the Department of Biotechnology, Government of India and financed by the All India Financial Institutions. BCIL has been actively involved in technology transfer, project consultancy, fund syndication, information dissemination, and manpower training & placement related to biotechnology over the last decade and half. It has assisted hundreds of clients including scientists, technologies, research institutions, universities, first entrepreneurs, the corporate sector, national and international organizations, central government, various state governments, banks and financial institutions.

keywords:N/A

N/A

Total Funding

78

Number of Employees

$6M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biotech Consortium India Limited (BCIL) News

2022-03-22 - GADVASU Conducts Workshop on ‘GM Crops in Animal Nutrition: Science & Safety Aspects’

... Ludhiana in association with Animal Nutrition Society of India (ANSI) and Biotech Consortium India Limited (BCIL), New Delhi conducted a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$300M78-24%N/A
#2
N/A7826%N/A
#3
N/A783%N/A
#4
$7.9M790%N/A
#5
$7.1M7923%N/A